Personalis Moderna sign agreement to use NeXT platform for mRNA cancer vaccine trials
Personalis (NASDAQ:PSNL) and Moderna (NASDAQ:MRNA) said they had signed a new agreement to continue using the PSNL's NeXT PlatformÂ as part of upcoming clinical studies testing cancer vaccine mRNA-4157/V940, jointly developed by Moderna and Merck (MRK).
The platform, which was also used in the vaccine candidateâs Phase 2b study, will be used to sequence genomic information from a patientâs tumor sample to identify the unique genetic mutations.
(PSNL) is tradingÂ ~8% higher.